Literature DB >> 19810418

Detection and identification of antinuclear antibodies (ANA) in a large community hospital.

G Verstegen1, M C Duyck, P Meeus, I Ravelingien, K De Vlam.   

Abstract

OBJECTIVE: Antinuclear antibodies (ANA) and their identification are important diagnostic tools in rheumatic diseases. We aimed to determine their prevalence in samples referred for ANA testing and to identify factors predicting more specific reactivities.
METHODS: We analyzed the first sample of 6422 consecutive patients for ANA. Positive samples were analyzed by indirect immunofluorescence (IIF) on Crithidia luciliae and by line immunoassay. We used multivariate logistic regression to detect predicting variables.
RESULTS: 42.6% of all patients were ANA positive of which 13.0% showed > or = one extractable nuclear antigen (ENA) reactivity with anti-SSA/Ro (5.5%), anti-SSB/La (2.9%), anti-Cenp-B (2.5%) and anti-histones (2.2%) as the most prevalent antibodies. Anti-double-stranded DNA antibodies (dsDNA) were present in 1.0%. The strongest overall predictor was ANA intensity regardless of pattern. Cenp-B however was best predicted by pattern. Anti-dsDNA and anti-histone were more frequent in samples with a homogenous as compared with a speckled pattern. Anti-SSA and anti-SSB were more frequent in females and anti-Sm in patients < or = 30 years.
CONCLUSIONS: The best overall predictor of antibodies to ENA or dsDNA is ANA intensity. Anti-Cenp-B is however best predicted by pattern. Samples with low ANA intensity (1+) may not need further testing unless a high clinical suspicion of ANA-associated disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19810418     DOI: 10.1179/acb.2009.049

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  5 in total

1.  Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity.

Authors:  Thomas Grüter; Anthonina Ott; Wolfgang Meyer; Sven Jarius; Markus Kinner; Jeremias Motte; Kalliopi Pitarokoili; Ralf Gold; Lars Komorowski; Ilya Ayzenberg
Journal:  J Neurol       Date:  2019-11-14       Impact factor: 4.849

2.  Antinuclear antibody testing: discordance between commercial laboratories.

Authors:  Aryeh M Abeles; Manuel Gomez-Ramirez; Micha Abeles; Shyoko Honiden
Journal:  Clin Rheumatol       Date:  2016-04-05       Impact factor: 2.980

3.  Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus.

Authors:  Li Rao; Guiyan Liu; Chunfen Li; Yajuan Li; Zhiguo Wang; Zijiao Zhou; Shengquan Tong; Xianming Wu
Journal:  Exp Ther Med       Date:  2013-04-08       Impact factor: 2.447

4.  Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria: Analytical study in a specialized health institute, one year follow-up.

Authors:  María Elena Soto; Nidia Hernández-Becerril; Ada Claudia Perez-Chiney; Alfredo Hernández-Rizo; José Eduardo Telich-Tarriba; Luis Eduardo Juárez-Orozco; Gabriela Melendez; Rafael Bojalil
Journal:  Results Immunol       Date:  2013-11-09

Review 5.  Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.

Authors:  Naomi Richardson; Sky T H Ng; David C Wraith
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.